logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • E.R. Squibb & Sons, L.L.C. drugs

    FiltersReset Filters
    18 results

    • augtyro

      (repotrectinib)
      E.R. Squibb & Sons, L.L.C.
      Usage: AUGTYRO is indicated for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) and for patients aged 12 and older with NTRK gene fusion-positive solid tumors that are advanced or metastatic, or where surgery poses severe risk, and have limited treatment options.

    • azactam

      (AZTREONAM)
      E.R. Squibb & Sons, L.L.C.
      Usage: AZACTAM is indicated for treating infections caused by susceptible Gram-negative bacteria, including urinary tract, lower respiratory tract, septicemia, skin and skin-structure, intra-abdominal, and gynecologic infections. It is also used adjunctively in surgical management of infections. Concurrent therapy with other antimicrobials may be necessary in seriously ill patients.

    • baraclude

      (entecavir)
      E.R. Squibb & Sons, L.L.C.
      Usage: BARACLUDE® (entecavir) is indicated for treating chronic hepatitis B virus infection in adults and pediatric patients aged 2 and older who show active viral replication and either elevated serum aminotransferases or histologically active disease.

    • cobenfy

      (xanomeline and trospium chloride)
      E.R. Squibb & Sons, L.L.C.
      Usage: COBENFY is indicated for the treatment of schizophrenia in adults.

    • eliquis

      (apixaban)
      E.R. Squibb & Sons, L.L.C.
      Usage: ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in nonvalvular atrial fibrillation, as well as for the prophylaxis and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). It also reduces the risk of recurrence of DVT and PE post-therapy.

    • empliciti

      (elotuzumab)
      E.R. Squibb & Sons, L.L.C.
      Usage: EMPLICITI is indicated for treating adult patients with multiple myeloma in combination with lenalidomide and dexamethasone after one to three prior therapies or with pomalidomide and dexamethasone after at least two prior therapies, including lenalidomide and a proteasome inhibitor.

    • evotaz

      (atazanavir and cobicistat)
      E.R. Squibb & Sons, L.L.C.
      Usage: EVOTAZ® is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents for adults and pediatric patients weighing at least 35 kg. Its use in treatment-experienced patients should be guided by baseline protease inhibitor resistance.

    • kenalog-10- triamcinolone acetonide injection, suspension

      (Triamcinolone Acetonide)
      E.R. Squibb & Sons, L.L.C.

    • kenalog-40- triamcinolone acetonide injection, suspension

      (Triamcinolone Acetonide)
      E.R. Squibb & Sons, L.L.C.

    • nulojix

      (BELATACEPT)
      E.R. Squibb & Sons, L.L.C.
      Usage: NULOJIX (belatacept) is indicated for the prevention of organ rejection in adult kidney transplant recipients, used in conjunction with basiliximab induction, mycophenolate mofetil, and corticosteroids. It is limited to EBV seropositive patients and is not approved for other transplanted organs.